Vitamin D: Benefits, Forms, Dosing, and Side Effects

Table of Contents

• 1. Overview
• 2. Forms and Bioavailability
• 3. Evidence for Health Benefits
• 4. Recommended Dosing
• 5. Safety and Side Effects
• 6. Drug Interactions
• 7. Dietary Sources
• 8. References
• References

Overview

Vitamin D is a fat-soluble vitamin that functions as a prohormone, regulating calcium and phosphorus homeostasis, bone mineralization, immune function, cell differentiation, and neuromuscular health [1][2][3]. It is unique among vitamins because it can be synthesized endogenously when ultraviolet B (UVB) radiation from sunlight strikes the skin and triggers the conversion of 7-dehydrocholesterol to previtamin D3, which becomes vitamin D3 (cholecalciferol) [1][2].

Vitamin D obtained from sun exposure, food, and supplements is biologically inert and must undergo two hydroxylations for activation. The first occurs in the liver, converting vitamin D to 25-hydroxyvitamin D (25(OH)D, also called calcidiol or calcifediol), the primary circulating form and the standard clinical marker of vitamin D status. The second hydroxylation occurs primarily in the kidney, producing 1,25-dihydroxyvitamin D (1,25(OH)2D, also called calcitriol), the physiologically active hormone form [1][2][3].

In foods and supplements, vitamin D exists in two main forms: D2 (ergocalciferol), derived from UV irradiation of ergosterol in yeast and plants, and D3 (cholecalciferol), produced from irradiation of 7-dehydrocholesterol from lanolin (sheep's wool) or, more recently, from lichen for a vegan-friendly source [1][2][4]. Both forms are well absorbed in the small intestine via passive diffusion and intestinal membrane carrier proteins, with fat in the gut enhancing absorption. Neither aging nor obesity alters vitamin D absorption from the gut [2].

Prevalence of Deficiency

Vitamin D deficiency is widespread. According to NHANES 2011-2014 data, 5% of the US population is at risk of deficiency (25(OH)D below 30 nmol/L or 12 ng/mL), and an additional 18% is at risk of inadequacy (30-49 nmol/L or 12-19.6 ng/mL) [1]. Most people in the United States consume less than recommended amounts: 92% of men, more than 97% of women, and 94% of people aged 1 year and older ingest less than the Estimated Average Requirement (400 IU) of vitamin D from food and beverages alone [1]. Sun exposure partially compensates, which is why serum levels are generally higher than dietary intake alone would predict.

Rates of deficiency vary significantly by race and ethnicity: 17.5% of non-Hispanic Black Americans are at risk of deficiency, compared to 7.6% of non-Hispanic Asians, 5.9% of Hispanics, and 2.1% of non-Hispanic White people [1].

Assessing Vitamin D Status

Serum 25(OH)D concentration is the standard indicator of vitamin D status, with a circulating half-life of approximately 15 days [1][2]. The Food and Nutrition Board (FNB) at the National Academies has established the following thresholds [1]:

25(OH)D Level	Health Status
< 30 nmol/L (< 12 ng/mL)	Deficient — risk of rickets (children) and osteomalacia (adults)
30 to < 50 nmol/L (12 to < 20 ng/mL)	Generally inadequate for bone and overall health
≥ 50 nmol/L (≥ 20 ng/mL)	Generally adequate for bone and overall health
> 125 nmol/L (> 50 ng/mL)	Potential adverse effects, particularly > 150 nmol/L (> 60 ng/mL)

It is important to note that assay variability across laboratories can produce falsely low or high results. The Vitamin D Standardization Program has developed procedures to improve measurement consistency [1][5]. The Endocrine Society does not recommend routine 25(OH)D testing in healthy individuals [6][7].

Signs and Symptoms of Deficiency

In children, vitamin D deficiency manifests as rickets — failure of bone tissue to properly mineralize, resulting in soft bones, skeletal deformities, developmental delay, hypocalcemic seizures, and dental abnormalities [1][2][8]. In infants, excessive sweating can be an early symptom [4]. In adults and adolescents, deficiency causes osteomalacia (bone softening) with bone pain and muscle weakness, as well as joint pain, chronic tension headaches, depression, insomnia, and hair loss [4][8]. Deficiency has also been linked to increased risk of depression, cognitive decline, heart attack, and mortality, although excessive vitamin D may also increase some of these risks [4].

Forms and Bioavailability

Vitamin D2 vs. Vitamin D3

Both forms raise serum 25(OH)D levels, but the evidence consistently favors D3 for maintaining adequate levels. A well-controlled study in New Zealand found that 1,000 IU/day of D3 maintained serum levels at 32 ng/mL through winter, while D2 at the same dose allowed levels to drop by 8 ng/mL, and placebo by 18 ng/mL (Logan, Br J Nutr 2013) [4][9]. A 12-week study in English women confirmed D3 raised 25(OH)D levels by 73% versus only 34% for D2 at 600 IU/day (Tripkovic, Am J Clin Nutr 2017) [1][9]. D2 may also cause erroneously low vitamin D blood test results [4]. Given that both forms are widely available and inexpensive, D3 is the preferred supplement form.

Calcifediol (25-hydroxyvitamin D)

Calcifediol, the 25-hydroxylated form of vitamin D, is three to five times more potent than D3 at raising serum 25(OH)D levels per equivalent microgram dose, with linear absorption that does not decline as blood levels rise [1][4][10]. However, calcifediol is available only as a prescription drug in the United States and is not found in dietary supplements. Small amounts of calcifediol occur naturally in animal-based foods, including beef liver, pork liver, egg yolk, and butter [4].

Tablets, Gummies, Liquids, and Sprays

Because vitamin D is fat-soluble, taking it with a meal containing fats significantly enhances absorption. A study found 32% higher peak blood levels when 50,000 IU of D3 was taken with a fat-containing breakfast versus a fat-free breakfast (Dawson-Hughes, J Acad Nutr Diet 2014) [4]. A striking study at the Cleveland Clinic found that simply switching vitamin D intake to the largest meal of the day increased serum levels by 56.7% on average (Mulligan, J Bone Min Res 2010) [4].

When taken only with water (not a meal), chewing a gummy may provide approximately twice the absorption of swallowing a tablet, likely because chewing and the small amount of oil in gummies better stimulate the digestive process (Wagner, Nutrients 2019) [4]. However, when taken with a meal, the difference between formats is likely minimal.

Oral sprays have been promoted for people with gastrointestinal absorption issues (Crohn's disease, ulcerative colitis). A study in India found that 1,000 IU as an oral spray raised levels by 10.5 ng/mL versus 4 ng/mL from a softgel, although both were taken 30 minutes after a meal rather than with a meal (Satia, Nutr J 2015) [4]. In healthy individuals, non-spray oral forms taken properly with food are equally effective and less expensive.

Key Principles for Form Selection

General supplementation: Vitamin D3 in any oral form (tablet, softgel, gummy, liquid), taken with the largest meal of the day.

Vegan option: Vitamin D3 sourced from lichen is available and animal-free. Vitamin D2 from yeast is also vegan but less effective at maintaining levels [1][4].

Malabsorption conditions: Consider oral sprays or higher doses of D3 with fat-containing meals [4].

Dose-response: As a rule of thumb, approximately 100 IU of D3 daily will raise serum 25(OH)D by about 1 ng/mL in non-obese adults. Obese individuals require roughly double this amount (approximately 200 IU per 1 ng/mL increase). Those starting with levels below 20 ng/mL may achieve approximately 60% greater increases than those already sufficient (Best, J Clin Endocrinol Metab 2021) [4]. With moderate supplementation (1,000 IU/day), serum levels typically reach their peak in approximately 6 weeks [4].

Evidence for Health Benefits

Bone Health and Fractures

Vitamin D regulates calcium and phosphorus absorption, maintains serum mineral concentrations for bone mineralization, and prevents hypocalcemic tetany. Without sufficient vitamin D, bones become thin, brittle, or misshapen [1][2].

Overall evidence: A review of 81 trials concluded that "vitamin D supplementation does not prevent fractures or falls, or have clinically meaningful effects on bone mineral density" — although it did not analyze results by vitamin D status and acknowledged that results in markedly deficient populations might differ (Bolland, Lancet Diab & Endocrin 2018) [4].

VITAL trial (bone substudy): Among 25,871 generally healthy adults (mean age 67.1), 2,000 IU/day D3 for a median of 5.3 years did not lower risk of total, hip, or nonvertebral fractures versus placebo. Most participants were vitamin D sufficient at baseline (only 2.4% below 12 ng/mL, 12.9% below 20 ng/mL). Exploratory analyses among those with starting levels below 12 or 20 ng/mL also showed no benefit (LeBoff, NEJM 2022) [1][4].

Benefit in deficient populations: A review of studies concluded that supplementation with 800 IU or more was "somewhat favorable" for hip and nonvertebral fracture prevention in people aged 65+, with a 30% reduction in hip fracture among those taking 792-2,000 IU/day versus no or low-dose vitamin D. Blood levels above 24 ng/mL appeared most beneficial (Bischoff-Ferrari, NEJM 2012) [4]. A 20-year follow-up of 68,132 postmenopausal women found that 400 IU D3 plus 1,000 mg calcium daily for 7 years reduced hip fracture risk by 23%, and by 50% in women also receiving hormonal therapy (Manson, JAMA 2024; Robbins, Menopause 2013) [4].

Women's Health Initiative — long-term follow-up: Daily 400 IU D3 plus 1,000 mg calcium for 7 years did not reduce fracture incidence during the trial, but over a median 22.3-year follow-up, the supplements were associated with a 6% reduction in any fracture and 16% reduction in hip fracture (Yao, JAMA Netw Open 2019) [1].

U-shaped relationship: A study of men aged 70-97 in Sydney found that those with vitamin D levels between 24 and 29 ng/mL were least likely to fracture. Men with levels at or below 14.4 ng/mL were 3.5 times as likely, and those above 29.2 ng/mL were 2.7 times as likely to fracture (Bleicher, J Bone Min Res 2014) [4].

Bone mineral density in sufficient adults: Among 687 adults (mean age 63) with sufficient vitamin D (mean 27 ng/mL), 2,000 IU/day D3 for 2 years did not improve bone mineral density or bone structure despite raising levels to 39 ng/mL (LeBoff, J Bone Miner Res 2020) [4]. In postmenopausal women with levels near 20 ng/mL, doses from 400 to 4,800 IU/day were not associated with significant bone mineral density effects compared to placebo (Smith, J Intern Med 2018) [4].

High-dose harm to bone: In adults with osteoporosis, 4,000 IU and 10,000 IU daily for 3 years reduced bone mineral density in the lower leg compared to 400 IU/day, with 10,000 IU also reducing forearm BMD. The loss was greater in women than men (Burt, JAMA 2019; Burt, J Bone Miner Res 2020) [4].

Fracture healing: Vitamin D deficiency may impede fracture healing. A case report described a 44-year-old man with severe deficiency (4 ng/mL) whose thighbone fracture failed to heal for 4 years despite multiple surgeries; after vitamin D correction (reaching 24 ng/mL), the fracture healed within 8 months (Moone, Nutrition 2021) [4]. However, giving vitamin D alone without adequate calcium did not improve wrist fracture healing in deficient postmenopausal women (Heyer, J Bone Miner Res 2021) [4].

Vegan women: Middle-aged and older women following a vegan diet without calcium and vitamin D supplementation had 3x the hip fracture risk, while vegan women supplementing with both nutrients did not have increased risk (Thorpe, Am J Clin Nutr 2021) [4].

USPSTF position: The USPSTF recommends against supplementation with 400 IU or less of vitamin D and 1,000 mg or less of calcium to prevent fractures in community-dwelling adults aged 50+ without osteoporosis or vitamin D deficiency. Evidence is insufficient for higher doses [1].

Synthesis: Vitamin D supplementation with calcium appears beneficial for fracture prevention primarily in people who are deficient (below 20 ng/mL), particularly older adults. There is no clear bone benefit from supplementation in people with adequate levels, and high doses (4,000+ IU/day) may actually reduce bone density.

Muscle Strength and Falls

Benefit in deficient older adults: A 9-month study in postmenopausal Brazilian women deficient in vitamin D (mean 15 ng/mL) found 1,000 IU/day increased lower-limb muscle strength by 25.3% and maintained lean mass, while placebo recipients lost lean mass (Cangussu, Osteoporos Int 2015) [4]. Similarly, 800 IU/day in Turkish women with levels averaging 10 ng/mL produced small but significant increases in hamstring and quadriceps strength (Apaydin, BMC Endocr Disord 2018) [4].

No benefit in sufficient adults: Multiple studies found 2,000-4,000 IU/day did not improve muscle strength or power in older adults with levels at or above 20 ng/mL (Bischoff-Ferrari, Osteoporos Int 2025; Houston, Am J Clin Nutr 2023; Grimnes, Clin Endocrinol 2017) [4].

High doses may harm muscles: In women with hyperparathyroidism and low vitamin D (mean 12.4 ng/mL), 2,800 IU/day for 3 months reduced handgrip strength by 9% and knee flexion strength by 13% (Bislev, Calcif Tissue Int 2018) [4]. Among postmenopausal women with adequate levels (21.4 ng/mL), 2,000 IU/day significantly decreased leg strength (Mason, JAGS 2016) [4]. Among healthy active older adults (mean age 75) with adequate vitamin D (22.4 ng/mL), 2,000 IU/day for 3 years modestly reduced self-reported physical activity (Hussein, J Nutr Health Aging 2025) [4].

In younger adults: A study of 39 previously untrained men (mean age 23) with low vitamin D (14 ng/mL) found that 8,000 IU/day for 3 months during a strength training program did not increase gains in muscle strength or lean body mass versus placebo plus training, despite raising levels to 57 ng/mL. In fact, the placebo group had greater gains in some exercises (Savolainen, Eur J Appl Physiol 2021) [4].

Falls — U-shaped dose response: A landmark study in women with levels below 20 ng/mL found those given 1,600-3,200 IU/day had the lowest fall rate (30% vs. 58% placebo). Women achieving levels of 32-38 ng/mL had the lowest rate (21%), while those reaching 38-46 ng/mL had the highest (72%) (Smith, J Steroid Biochem Mol Biol 2017) [4]. High monthly doses (60,000 IU/month) increased fall risk in older adults (Bischoff-Ferrari, JAMA Intern Med 2016) [4]. Among older adults with adequate vitamin D (22 ng/mL), those given 1,000-4,000 IU/day had 87% increased risk of serious falls compared to 200 IU/day (Appel, Ann Intern Med 2020) [4].

USPSTF position: The USPSTF concluded with moderate certainty that vitamin D supplementation does not reduce falls or fall-related injuries in community-dwelling adults aged 65+ without osteoporosis or deficiency [1].

Cancer

Incidence: Clinical trials consistently show vitamin D supplementation does not reduce overall cancer incidence in people with adequate vitamin D levels. The VITAL trial (25,871 participants, 2,000 IU/day, median 5.3 years) found no reduction in breast, prostate, or colorectal cancer rates. However, normal-weight participants had greater reductions in cancer incidence than those with overweight or obesity (Manson, NEJM 2018) [1][4].

Mortality: Three meta-analyses of clinical trials found vitamin D supplementation significantly reduces total cancer mortality by 12-13%, with most benefit from daily dosing rather than bolus doses [1]. The VITAL trial, excluding the first 2 years, showed a 25% lower rate of cancer death with vitamin D (Manson, NEJM 2018) [4]. A secondary analysis found advanced (metastatic or fatal) cancer was reduced by 17% overall and by 38% in those with normal BMI (Chandler, JAMA Netw Open 2020) [4]. A European trial of 2,157 adults aged 70+ found 2,000 IU/day D3 reduced invasive cancer risk by 24%, which increased to 61% when combined with omega-3s and home strength training (Bischoff-Ferrari, Front Nutr 2022) [4].

WHI long-term follow-up: 400 IU D3 plus 1,000 mg calcium daily did not affect cancer incidence during the 7-year trial, but reduced cancer mortality by 7% over a 22.3-year median follow-up (WHI, 2024) [1].

Colorectal cancer: Higher vitamin D levels (30-40 ng/mL) were associated with 19-27% lower colorectal cancer risk compared to levels below 12 ng/mL in a large case-control study (McCullough, J Natl Cancer Inst 2018) [1][4]. A study found levels around 27.9 ng/mL were associated with just 33% of the risk of immune-infiltrated colorectal tumors, and levels around 37.4 ng/mL with just 10% of the risk, compared to the lowest levels (~19 ng/mL) (Song, Gut 2015) [4]. Among patients with advanced colorectal cancer, levels at or above 24.1 ng/mL at start of chemotherapy were associated with 19% less disease progression and 34% lower mortality (Yuan, Clin Cancer Res 2019) [4]. However, supplementation trials (1,000 IU D3 and/or 1,200 mg calcium daily) have not reduced precancerous polyps in people with adequate levels (Baron, NEJM 2015) [4].

Breast cancer: Women with the highest vitamin D levels at diagnosis were approximately twice as likely to survive over 5-20 years compared to those with the lowest levels (Mohr, Anticancer Research 2014) [4]. In postmenopausal women with low vitamin D and breast cancer, 2,000 IU/day during chemotherapy raised complete response rates to 43% vs. 24% for placebo (Omodei, Nutr Cancer 2025) [4]. However, in women with adequate levels (mean 29 ng/mL), very high-dose D3 (40,000 IU/day) before surgery did not slow tumor growth and caused more fatigue (Arnaout, Breast Cancer Res Treat 2019) [4].

Prostate cancer: Both low and high vitamin D levels are associated with increased risk. The "sweet spot" associated with lowest risk is 23-29 ng/mL (Kristal, Cancer Epi Biomark Prev 2014) [4]. More recent studies and meta-analyses have generally found no relationship between 25(OH)D levels and prostate cancer risk, although higher levels may be associated with lower mortality from the disease [1].

Pancreatic cancer: Levels of 20-29 ng/mL were associated with 25% lower risk, and above 30 ng/mL with 29% lower risk compared to below 20 ng/mL, in a review of 5 large studies (Wolpin, Cancer Epidemiol Biomarkers Prev 2011) [4]. However, the NIH notes an investigation that found increased pancreatic cancer risk at levels at or above 40 ng/mL [1].

Overall mortality from all causes: A study of over 300,000 UK adults found mortality risk decreased as vitamin D levels rose to 24 ng/mL and then leveled off (Fan, J Clin Endocrinol Metab 2020) [4]. A meta-analysis found D3 supplementation reduced overall mortality by 11%, while D2 had no effect (Chowdhury, BMJ 2014) [4]. A Danish population study found 20-24 ng/mL was associated with the lowest mortality risk, with levels of 56 ng/mL conferring 42% higher mortality (Durup, J Clin Endocrinol Metab 2012) [4].

Cancer treatment adjunct: Among 339 people with advanced solid tumors in Italy with low vitamin D (mean 13 ng/mL), supplementing during checkpoint inhibitor therapy reduced death risk by 33% and treatment discontinuation by 28% (Bersanelli, Cancer Immunol Immunother 2023) [4]. In people with digestive tract cancers positive for p53 gene mutations, 2,000 IU/day for 5 years reduced relapse or death to 30.6% versus 80.9% for placebo (Kanno, JAMA Open 2023) [4]. In 150 palliative care cancer patients with low vitamin D, 4,000 IU/day for 12 weeks slowed the rate of fentanyl dose increase and reduced fatigue (Frankling, Cancers 2021) [4].

Synthesis: Vitamin D supplementation does not appear to reduce cancer incidence in vitamin D-sufficient populations but does reduce cancer mortality by approximately 12-25%, particularly with daily dosing and in normal-weight individuals. Maintaining levels of 20-35 ng/mL appears optimal. Higher levels (above 40 ng/mL) do not appear to provide additional benefit and may increase certain risks.

Cardiovascular Disease

Observational data: A meta-analysis of 34 observational studies (180,667 participants) found CVD event risk was 10% lower for each 10 ng/mL increase in 25(OH)D [1]. However, a Danish study (247,574 adults) found both low (~5 ng/mL) and high (~50 ng/mL) levels associated with greater CVD mortality risk — a U-shaped relationship [1].

VITAL trial: 2,000 IU/day D3 for a median of 5.3 years produced no significant reduction in heart attacks, strokes, coronary revascularization, or cardiovascular deaths in 25,871 adults (mean starting level 30.8 ng/mL) (Manson, NEJM 2018) [1][4].

Other trials: A New Zealand trial (5,110 adults, 100,000 IU monthly, median 3.3 years) found no effect on any cardiovascular endpoint [1]. In deficient heart failure patients given 4,000 IU/day for 3 years, there was no mortality reduction and increased need for mechanical circulatory support implants (Zittermann, Eur Heart J 2017) [4]. In another heart failure study (UK, 163 patients with levels below 20 ng/mL), 4,000 IU/day modestly improved heart output but reduced walking distance by 4%, while placebo improved walking distance by 4% — possibly due to levels reaching ~50 ng/mL, which is associated with increased falls (Witte, J Am Coll Cardiol 2016) [4].

Blood pressure: A comprehensive review of 46 trials concluded vitamin D is ineffective for lowering blood pressure, regardless of starting levels, and should not be used as an antihypertensive agent (Beveridge, JAMA Intern Med 2015) [4]. However, a single study found that 2,000 IU/day D3 for 6 months in people already taking nifedipine reduced systolic BP by 6.2 mmHg and diastolic by 4.2 mmHg, with levels rising from 19.4 to 34.1 ng/mL (Chen, Atherosclerosis 2014) [4].

Cholesterol: In statin-treated patients with low vitamin D (approximately half below 20 ng/mL), 2,000 IU/day D3 for 6 months significantly improved cholesterol: total cholesterol fell by 22.1 mg/dL, triglycerides by 28.2 mg/dL, LDL by 20.2 mg/dL, and HDL increased by 8.2 mg/dL versus placebo (Qin, Clin Nutr 2015) [4]. However, giving high-dose vitamin D to non-deficient obese adolescents increased triglycerides by 32% and total cholesterol by 9% (Javed, Pediatric Obesity 2015) [4].

Arterial stiffness: In overweight African-Americans with vitamin D deficiency (mean ~15 ng/mL), high doses (60,000 or 120,000 IU monthly, raising levels to ~35 ng/mL) improved arterial stiffness by 8-10%, but a lower dose (18,000 IU/month, raising levels to 23 ng/mL) did not (Raed, PLOSOne 2017) [4].

Synthesis: Despite strong observational associations between low vitamin D and cardiovascular risk, clinical trials do not support supplementation for CVD prevention, even in deficient populations. The exception is a potential synergistic benefit with statin therapy, where maintaining sufficient vitamin D levels may improve lipid profiles.

Diabetes and Insulin Resistance

Type 1 diabetes risk: Higher serum vitamin D levels (24-31 ng/mL) have been associated with the lowest risk of type 1 diabetes. Compared to this range, risk was 2.5x higher at 17-24 ng/mL and 3.5x higher below 17 ng/mL (Gorham, Diabetologia 2012) [4].

Prediabetes with vitamin D deficiency: In a large 2.5-year trial, 4,000 IU/day D3 in people with prediabetes and adequate vitamin D (mean 27.7 ng/mL) did not reduce overall type 2 diabetes risk. However, among those with levels below 12 ng/mL, vitamin D reduced diabetes risk by 62%. When only protocol-adherent participants were considered, supplementation reduced diabetes risk by 16% overall and participants were 31-45% more likely to achieve normal blood sugar regulation (Pittas, NEJM 2019; Hsia, Diabetes Res Clin Pract 2023) [1][4].

Insulin resistance: In overweight older adults in Lebanon with very low vitamin D (mean 10 ng/mL), 10,000 IU D3 three times weekly for 6 months modestly reduced insulin resistance and fasting blood sugar (Hajj, J Nutr Health Aging 2018) [4]. In healthy Japanese adults with low vitamin D (mean 13 ng/mL), 420 IU/day for 1 year decreased fasting glucose from 88.3 to 85.3 mg/dL and improved insulin resistance (Sun, Nutr Res 2016) [4].

Established type 2 diabetes: In a large US trial, 4,000 IU/day for 48 weeks in people with stable type 2 diabetes who were not deficient (mean 27 ng/mL) did not improve any measure of blood sugar control (Angellotti, J Endocrine Society 2018) [4]. A systematic review and meta-analysis of 35 trials (43,407 adults) found vitamin D had no significant effects on glucose homeostasis, insulin secretion or resistance, or HbA1c, irrespective of population or dose [1].

VITAL trial (diabetes substudy): 2,000 IU/day D3 for approximately 5.5 years did not reduce type 2 diabetes risk in over 22,000 healthy older adults, even among those with baseline levels below 20 ng/mL (Tobias, Nat Commun 2025) [4].

Gestational diabetes: A 6-week study of 56 women with gestational diabetes found that 1,000 mg calcium plus 50,000 IU D3 at weeks 0 and 3 significantly lowered fasting glucose and improved insulin sensitivity compared to placebo (Asemi, Diabetologia 2014) [4].

Diabetic neuropathy: In 68 people with type 2 diabetes, low vitamin D (mean 15 ng/mL), and peripheral neuropathy, 5,000 IU/day for 8 weeks in addition to standard treatment modestly reduced overall pain scores compared to standard treatment alone (Pinzon, J Pain Res 2021) [4].

Synthesis: Vitamin D supplementation helps prevent type 2 diabetes primarily in people who are severely deficient (below 12 ng/mL). It does not improve glycemic control in people with established diabetes or adequate vitamin D levels.

Depression and Mood

Observational data: A meta-analysis of 14 observational studies (31,424 adults) found an association between deficient or low 25(OH)D levels and depression [1]. Lower levels (below 20 ng/mL) and lower dietary intake (less than 100 IU) have been associated with higher depression risk (Milaneschi, J Clin Endocrinol Metab 2010; Bertone-Johnson, Am J Clin Nutr 2011) [4].

Clinical trials — mostly negative: A meta-analysis of 9 trials (4,923 adults) found no significant reduction in depressive symptoms after vitamin D supplementation, using doses from 400 IU/day to 40,000 IU/week [1]. The VITAL trial found 2,000 IU/day for a median of 5.3 years did not affect depression incidence or mood scores in 16,657 adults (Okereke, JAMA 2020) [1][4]. A year-long Dutch trial in older adults with low vitamin D (mean 18 ng/mL) found 1,200 IU/day did not improve depression or anxiety (de Koning, Am J Clin Nutr 2019) [4]. A Danish study of 62 people with diagnosed depression found 2,800 IU/day for 6 months did not improve depression even among those deficient below 10 ng/mL (Hansen, BMC Res Notes 2019) [4].

Exception — diabetes and depression: Among 64 people with type 2 diabetes and mild-moderate depression with low vitamin D (mean 15 ng/mL), 4,000 IU D3 daily for 3 months decreased depression symptoms by 27.6% versus 10.8% with placebo, and also modestly improved HbA1c (Omidian, Diabetes Metab Syndr 2019) [4].

High-dose risk: A large Australian study found that monthly 60,000 IU D3 for 5 years in adults with adequate vitamin D increased antidepressant use by 10% compared to placebo (Rahman, Int J Geriatr Psychiatry 2022) [4].

Synthesis: Despite plausible mechanisms and epidemiological associations, vitamin D supplementation does not prevent or treat depression in most populations. The sole exception may be in people with comorbid diabetes and vitamin D deficiency.

Cognitive Function and Dementia

Dementia risk: A study of 1,658 older US adults found those with 25(OH)D below 10 ng/mL were 125% more likely to develop dementia and 122% more likely to develop Alzheimer's disease over 5.6 years compared to levels at or above 20 ng/mL (Littlejohns, Neurology 2014) [4]. A French study of 916 adults (mean age 73) found levels below 20 ng/mL were associated with nearly triple the risk of Alzheimer's over 11.4 years (Feart, Alzheimers Dement 2017) [4]. Higher midlife vitamin D levels were associated with lower tau protein deposits on PET scans 16 years later, a major Alzheimer's marker (Mulligan, Neurology 2026) [4]. A French study found women consuming more than 444 IU/day of dietary vitamin D were 77% less likely to develop Alzheimer's over 7 years (Annweiler, J Gerontol A Biol Sci Med 2012) [4].

Cognitive improvement in MCI: A 12-month Chinese trial in 181 older adults with mild cognitive impairment (MCI) found 400 IU/day modestly improved verbal and performance tasks, raising levels from 19 to 23.4 ng/mL (Hu, J Neurol Neurosurg Psychiatry 2018) [4]. Another Chinese trial in 183 MCI patients found 800 IU/day improved overall cognitive function scores and increased telomere length (Yang, J Alzheimers Dis 2020) [4].

No benefit in sufficient adults or with high doses: A 2-year UK trial of 340 older adults with low vitamin D (16.8 ng/mL) found 4,000 IU/day did not improve cognitive function (Corbett, J Am Med Dir Assoc 2025) [4]. High-dose D3 (10,000 IU three times weekly) for 6 months did not improve cognition in MCI patients with mostly sufficient levels (Montero-Odasso, JAMA Open 2023) [4]. An Australian study of 4,019 healthy older adults found monthly 60,000 IU D3 for up to 5 years did not improve cognition regardless of baseline vitamin D status (Pham, J Am Geriatr Soc 2023) [4].

Calcitriol concern: A Taiwanese study found regular daily calcitriol (prescription vitamin D) use was associated with 1.8x higher Alzheimer's risk (Lai, Aging Cell 2022) [4]. This finding requires cautious interpretation but warrants awareness.

Synthesis: Maintaining levels at or above 20 ng/mL may reduce dementia risk, and low-dose supplementation may modestly improve cognition in people with MCI and low vitamin D. High doses do not provide cognitive benefit and may carry risks.

Respiratory Infections and COVID-19

Respiratory infections: A meta-analysis of 25 studies found vitamin D supplementation protects against acute respiratory tract infection primarily in people very deficient (below 10 ng/mL), reducing risk by 42% overall and by 70% with daily or weekly dosing (Martineau, BMJ 2017) [4]. Large monthly doses (60,000-100,000 IU) did not reduce infections (Murdoch, JAMA 2012; Pham, Lancet Diabetes Endocrinol 2021) [4]. A study in Indian adults found 2,000 IU/day for 6 months modestly reduced acute respiratory episodes, even among those with adequate baseline levels (Gundapuneni, Int J Med Pharma Res 2025) [4]. A study in Danish children (mean baseline level 32 ng/mL) found 800 IU/day for 24 weeks during winter resulted in 17% fewer sick days and 43% fewer days of respiratory infections with fever (Clerico, Eur J Nutr 2025) [4].

COVID-19 prevention: A Mexican study of 302 unvaccinated healthcare workers (64% deficient) found 4,000 IU/day D3 for 30 days reduced COVID-19 infection risk by 77% (Villasis-Keever, Arch Med Res 2022) [4].

COVID-19 severity: Low vitamin D (below 20 ng/mL) has been consistently associated with more severe disease. Among hospitalized COVID-19 patients with deficiency, supplementation reduced hospitalization by 50% and supplemental oxygen duration by 42% in a Belgian study (De Niet, Nutrients 2022) [4]. However, having levels at or above 40 ng/mL was associated with 365% higher death risk compared to 20-30 ng/mL in a UK study (Subramanian, Am J Clin Nutr 2022) [4]. Single very high doses (200,000-540,000 IU) at admission did not reduce outcomes (Murai, JAMA 2021; Cannata-Andia, BMC Med 2022) [4].

Autoimmune Disease

Rheumatoid arthritis: The VITAL trial found 2,000 IU/day D3 reduced autoimmune disease risk by 22% overall, with an apparent 42% reduction in rheumatoid arthritis specifically (Hahn, BMJ 2022) [4]. Lower vitamin D levels have been associated with greater disease activity and severity in established RA (Hong, Rheumatology 2014; Mouterde, J Rheumatol 2020) [4].

Multiple sclerosis: Epidemiological studies consistently show lower 25(OH)D levels are associated with higher MS risk. A Finnish study found women with 25(OH)D below 12 ng/mL had 43% higher MS risk than those at or above 20 ng/mL, and levels below 30 nmol/L were associated with double the risk [1][4]. However, clinical trials (12 trials, 933 participants) found no effect of vitamin D supplementation on MS relapse rates or disability progression (Cochrane Review 2018) [1][4]. A study of 182 adults with clinically isolated syndrome found that vitamin D supplementation (1,000-10,000 IU/day) did not decrease conversion to MS diagnosis (Butzkueven, Brain 2023) [4].

Hashimoto's thyroiditis: Among 179 newly diagnosed women with low vitamin D (mean 15 ng/mL), 800 IU/day for 6 months significantly decreased TSH and thyroid autoantibodies, with greater benefit when combined with levothyroxine (Jiang, Am J Transl Res 2023) [4]. However, the VITAL trial noted an apparent 64% increase in thyroid disease risk with vitamin D supplementation [4].

Graves' disease: 2,800 IU/day for 1 year in addition to anti-thyroid medication did not improve remission rates in people with generally adequate vitamin D levels (Grove-Laugesen, Thyroid 2023) [4].

Asthma and COPD

Asthma: A Cochrane review of 7 trials found oral vitamin D (average 900 IU/day) reduced asthma attacks requiring oral steroids from 0.44 to 0.22 per year and halved hospitalization risk from 6% to 3% (Martineau, Cochrane Database Syst Rev 2016) [4]. A subsequent review found these benefits were limited to people with very low vitamin D (below 10 ng/mL) (Jolliffe, Lancet Respir Med 2017) [4]. A study in Japanese schoolchildren found 800 IU/day for 2 months significantly improved asthma control, with benefit lasting 4 months after discontinuation (Tachimoto, Allergy 2016) [4]. In contrast, 4,000 IU/day for 48 weeks did not benefit US children with vitamin D levels mostly above 20 ng/mL (Forno, JAMA 2020) [4]. Prenatal supplementation with 4,400 IU/day reduced children's asthma risk by 74% in deficient mothers only (Shadid, Am J Clin Nutr 2023) [4].

COPD: In people with COPD and levels below 20 ng/mL, 2,000 IU/day equivalent significantly reduced exacerbation risk (Martineau, Lancet Resp Med 2014) [4]. Benefit was greatest among those below 10 ng/mL (Lehouck, Ann Intern Med 2012) [4]. No benefit was observed in those with adequate levels.

Vertigo (BPPV)

Multiple studies found vitamin D supplementation reduces recurrence of benign paroxysmal positional vertigo (BPPV) in people with low levels. In a Korean study, 400 IU D3 plus 500 mg calcium twice daily for 12 months reduced BPPV recurrence by 24%, with greatest benefit in severely deficient patients (below 10 ng/mL) (Jeong, Neurology 2020) [4]. Another Korean study found only 9.5% of those given 7,000 IU weekly experienced recurrence versus 44.4% of placebo recipients (Kong, Laryngoscope Investig Otolaryngol 2024) [4]. However, vitamin D supplementation in BPPV patients did not significantly improve balance or decrease falls (Huang, Aging Clin Exp Res 2025) [4].

Skin Conditions

Eczema: In children and adults with moderate-severe eczema, achieving levels at or above 20 ng/mL significantly reduced severity; levels at or above 30 ng/mL provided no further benefit (Sanchez-Armendariz, Int J Dermatol 2018) [4]. In children with severe eczema, 1,600 IU/day for 3 months produced 75%+ improvement in 39% versus 7% of placebo (Mansour, Pharmacol Res Perspect 2020) [4].

Psoriasis: A Norwegian study of 122 adults with mild psoriasis found high-dose D3 did not reduce severity despite raising levels from 15 to 30 ng/mL (Jenssen, JAMA Dermatol 2023) [4].

Acne: In adults with acne and vitamin D deficiency, 1,000 IU/day for 2 months reduced inflammatory lesions by 34.6% versus 5.8% with placebo (Lim, PLoS One 2016) [4]. No benefit is expected in non-deficient individuals.

Chronic hives (urticaria): In 120 deficient people with chronic urticaria (mean 14 ng/mL), 60,000 IU every 2 weeks for 12 weeks significantly reduced disease severity and inflammatory cytokines (Mony, Clinica Chimica Acta 2020) [4].

NAFLD (Non-Alcoholic Fatty Liver Disease)

In 40 adults with significant liver fat and low vitamin D (mean 11.8 ng/mL), weekly 20,000 IU D3 (~2,857 IU/day equivalent) for 4 weeks reduced liver fattiness by approximately 5% (Papaostoli, J Gastrointestin Liver Dis 2016) [4]. A 6-month study found 2,000 IU/day raised levels above 30 ng/mL in 75% of NAFLD patients without inflammation but only 15% of those with steatohepatitis; only those achieving adequate levels showed improvements in liver function markers (Dasarathy, J Nutr 2017) [4].

Pregnancy

Adequate vitamin D during pregnancy is associated with better infant growth, decreased risk of preterm labor, preeclampsia, and gestational diabetes [4]. In an Indian study, supplementing deficient pregnant women with vitamin D (dosage based on deficiency severity) raised levels to 32 ng/mL and halved the rate of preterm labor, preeclampsia, and gestational diabetes (44% without vitamin D vs. 20.3% with). Babies had higher average birth weight (5.72 vs. 5.28 lbs) (Sablok, Clin Endocrinol 2015) [4]. A US study found vitamin D reduced pregnancy loss and improved infant Apgar scores but did not reduce preterm birth or NICU admission in women with already sufficient levels (Persad, Am J Obstet Gynecol 2021) [4].

Prenatal vitamin D may reduce childhood asthma risk: Among mothers who were deficient and received 4,400 IU/day starting at 10-18 weeks gestation, children's risk of asthma by age 6 was reduced by 74% compared to deficient mothers receiving placebo (Shadid, Am J Clin Nutr 2023) [4]. High-dose prenatal vitamin D (2,800 IU/day from week 24) reduced tooth enamel defects in children by 50% at age 6, and children of deficient mothers had greater bone mineral density at ages 4-7 (Norrisgaard, JAMA Pediatr 2019; Curtis, JBMR Plus 2022; Moon, Am J Clin Nutr 2024) [4]. High-dose vitamin D during pregnancy did not improve children's motor, language, or cognitive development by age 6 (Sass, JAMA Netw Open 2020) [4].

Weight and Body Composition

Clinical trials do not support vitamin D supplementation for weight loss. A meta-analysis of 12 vitamin D supplementation trials found no effect on body weight or fat mass without caloric restriction [1]. Vitamin D supplementation did not promote weight loss in obese postmenopausal women following a reduced-calorie diet and exercise program (Mason, Am J Clin Nutr 2014) [4]. However, weight loss itself raises vitamin D levels, likely by releasing vitamin D stored in fat tissue [4].

Allergies

Higher serum vitamin D levels are associated with reduced allergy risk in children but not adults. Among children with serum vitamin D below 15 ng/mL, allergic sensitization was more common for 11 of 17 allergens tested, with strongest associations for oak (5x risk), peanut (2.4x), and ragweed (1.8x) (Sharief, J Allergy Clin Immunol 2011) [4]. In adults with seasonal allergies and low vitamin D (~14 ng/mL), supplementation in addition to antihistamine treatment significantly reduced nasal symptoms (Bakhshaee, Eur Arch Otorhinolaryngol 2019; Rana, Indian J Otolaryngol 2025) [4].

Erectile Dysfunction

In men with erectile dysfunction and low vitamin D (mean 14 ng/mL), 4,000 IU/day D3 for 3 months improved erectile function and sexual desire when combined with tadalafil versus tadalafil alone (Demirci, Urol Int 2021) [4]. However, among older men with adequate vitamin D (80% above 20 ng/mL), monthly 60,000 IU D3 for 3 years did not prevent or improve erectile dysfunction (Romero, Clin Nutr ESPEN 2024) [4].

Crohn's Disease and IBS

In a small study of mild-moderate Crohn's disease with low vitamin D (mean 16 ng/mL), raising levels to 40 ng/mL over 24 weeks decreased Crohn's Disease Activity Index scores by 112 points (Yang, Clin Transl Gastroenterol 2013) [4]. The American Gastroenterological Association advises monitoring for vitamin D deficiency in all individuals with inflammatory bowel disease (Hashash, Gastroenterology 2024) [4]. A UK trial in 135 adults with IBS found 3,000 IU/day did not reduce symptom severity despite raising levels from 19 to 37 ng/mL (Williams, Eur J Nutr 2021) [4].

Fibromyalgia

In 30 adults with fibromyalgia and vitamin D below 24 ng/mL, raising levels from 19 to ~50 ng/mL with 2,400 IU/day for 20 weeks decreased pain by 20 points on a 100-point scale. Pain returned after supplementation ended (Wepner, Pain 2013) [4]. A study in 80 women with adequate vitamin D (above 20 ng/mL) found 50,000 IU weekly for 12 weeks did not improve symptoms (Lozano-Plato, Clin Rheumatol 2021) [4].

Statin Interactions and Benefits

Vitamin D adequacy may blunt statin-related decline in exercise performance. In deficient people with type 2 diabetes, combining simvastatin with vitamin D (60,000 IU/week) preserved cardiovascular fitness and skeletal muscle mitochondrial content, while simvastatin alone reduced both (Singla, J Diabetes 2017) [4]. Statin users had a 21.4% smaller increase in vitamin D levels than non-users, suggesting higher doses may be needed (Bischoff-Ferrari, JAGS 2017) [4]. However, vitamin D supplementation (2,000 IU/day) did not prevent or reverse existing statin-related muscle pain in a large trial of 2,083 adults (Hlatky, JAMA Cardiol 2022) [4].

Recommended Dosing

Recommended Dietary Allowances (RDAs)

From the Food and Nutrition Board at the National Academies [1]:

Age Group	RDA
0-12 months	10 mcg (400 IU)
1-70 years	15 mcg (600 IU)
> 70 years	20 mcg (800 IU)
Pregnancy/Lactation	15 mcg (600 IU)

Adequate Intake (AI), not RDA

The Endocrine Society (2024) recommends routine vitamin D supplementation for children and teens (1-18 years), pregnant women, adults with prediabetes, and adults aged 75+, but not for healthy adults aged 19-74 [6][7].

Tolerable Upper Intake Levels (ULs)

Age	UL
0-6 months	25 mcg (1,000 IU)
7-12 months	38 mcg (1,500 IU)
1-3 years	63 mcg (2,500 IU)
4-8 years	75 mcg (3,000 IU)
9+ years, including pregnancy	100 mcg (4,000 IU)

While signs of toxicity are unlikely below 10,000 IU/day, the FNB noted that even intakes below the UL may have adverse effects over time, and recommended avoiding serum 25(OH)D levels above 50-60 ng/mL [1].

Practical Dosing by Indication

General supplementation (to maintain levels of 20-30 ng/mL): 600-1,000 IU D3 daily, taken with the largest meal of the day [1][4].

Correcting deficiency (below 20 ng/mL): 1,000-2,000 IU D3 daily for 6-8 weeks, then reassess. Obese individuals may require 2,000-4,000 IU/day [4].

Older adults (75+): 800-1,000 IU D3 daily is recommended by the Endocrine Society. Taking with calcium (800-1,200 mg/day from food and supplements combined) improves bone outcomes [1][6].

Breastfed infants: 400 IU D3 daily starting shortly after birth, per the American Academy of Pediatrics [1].

Pregnancy: 600-1,000 IU D3 daily. Higher doses (up to 4,000 IU/day) may be indicated in deficient women but should be discussed with a healthcare provider [4].

Statin users: Statin users may require 21% higher doses to achieve the same level increase (Bischoff-Ferrari, JAGS 2017) [4]. Maintaining adequate vitamin D appears to improve statin efficacy for cholesterol reduction.

Avoid bolus dosing: Large infrequent doses (monthly or annual) are consistently less effective and may be harmful. Studies show 60,000 IU/month or 500,000 IU/year increased falls, fractures, and potentially cancer-related deaths compared to daily dosing [4]. Daily or weekly dosing is preferred.

Dr Brad Stanfield's MicroVitamin includes 1,000 IU of Vitamin D3 (cholecalciferol) — a daily dose that aligns with maintaining adequate 25(OH)D levels for most adults, combined with Vitamin K2 MK-7 (90 mcg) and Boron (1 mg) for synergistic bone health support.

How to Read a Supplement Label

Vitamin D is measured in International Units (IU) or micrograms (mcg). The conversion: 1 mcg = 40 IU, so 1,000 IU = 25 mcg. The FDA Daily Value (DV) for vitamin D is 20 mcg (800 IU) for adults and children aged 4+. Products listing 100% DV contain 800 IU [1].

Target Blood Levels

Based on the totality of evidence across multiple health outcomes, maintaining 25(OH)D levels of 20-30 ng/mL appears optimal. Levels below 20 ng/mL increase risk across many conditions. Levels above 30 ng/mL have not consistently shown additional benefit and levels above 40-50 ng/mL are associated with potential adverse effects including increased falls, fractures, cardiovascular events, and mortality [1][4].

Safety and Side Effects

Common Side Effects

At recommended doses (600-1,000 IU/day), side effects are uncommon. At higher doses (4,000+ IU/day), potential effects include [1][4]:

• Nausea, vomiting, loss of appetite
• Constipation
• Muscle weakness
• Headache, confusion, irritability
• Metallic taste
• Fatigue

Toxicity (Hypercalcemia)

Vitamin D toxicity results from excessive supplementation (never from sun exposure, as the body self-regulates cutaneous production). Toxicity causes hypercalcemia (serum calcium > 11.1 mg/dL) with serum 25(OH)D typically above 150 ng/mL [1][4]. Symptoms progress from nausea and weakness to dehydration, kidney stones, kidney failure, cardiac arrhythmias, calcification of soft tissues, and death in extreme cases [1][4].

Adverse Effects at Levels of 30-50 ng/mL

Even below classic toxicity thresholds, levels above 30 ng/mL are associated with increased risks in several studies [4]:

• Bone density loss: 4,000 and 10,000 IU/day for 3 years reduced BMD versus 400 IU/day (Burt, JAMA 2019) [4]
• Falls and fractures: Achieving levels of 38-48 ng/mL was associated with the highest fall rates in multiple studies (Smith 2017; Appel 2020) [4]
• All-cause mortality: A Danish study found 42% higher mortality at 56 ng/mL versus 20 ng/mL (Durup 2012); an Australian study found 60,000 IU/month for 5 years was associated with 29% increased all-cause mortality (Joseph 2022) [4]
• Cancer-related mortality: Monthly 60,000 IU D3 was associated with 24% increased cancer-related death during the last 3 years of a 5-year study (Neale, Lancet Diabetes Endocrinol 2022) [4]
• Sleep disruption: Some research suggests high-dose vitamin D may interfere with melatonin production, and levels above 32 ng/mL may worsen sleep quality [4]
• DNA damage: High monthly doses (50,000 IU) increased markers of DNA damage linked to cancer risk in a resistance training study (Draxler, Redox Biol 2023) [4]

Harm from Single Large Doses

Very high single doses are particularly harmful. Giving 540,000 IU to critically ill, deficient patients increased mortality compared to placebo — the study was stopped early (Nat Heart Lung Blood Inst, NEJM 2019) [4]. Annual 500,000 IU doses increased falls by 31% (Sanders, JAMA 2010) [4]. High-dose vitamin D increases production of 24-hydroxylase, an enzyme that inactivates the active form of vitamin D, potentially explaining paradoxical harm (Owens, Med Sci Sports Exerc 2017) [4]. An Australian study found adding a one-time 50,000 IU bolus at the beginning of daily 1,000 IU dosing did not raise levels faster and may have hampered increases in those with already sufficient levels (Feehan, Exp Gerontol 2021) [4].

Kidney Stones

The combination of high calcium intake (~2,100 mg/day) with moderate vitamin D (~765 IU/day) increased kidney stone risk by 17% over 7 years in the WHI trial. However, shorter trials of vitamin D alone or with calcium found increased hypercalcemia and hypercalciuria but not kidney stones [1].

Special Populations

Pregnancy: 600-1,000 IU/day appears safe. Higher doses should be discussed with a healthcare provider [1][4].

Infants: 400 IU/day is adequate and safe. 1,000 IU/day is at the UL for infants up to 6 months — a study found 1,600 IU/day caused excessively high levels (Gallo, JAMA 2013) [4].

Obesity: Subcutaneous fat sequesters vitamin D, requiring higher doses to achieve the same serum levels. Approximately double the standard dose may be needed [1][4].

Kidney disease: Impaired conversion of 25(OH)D to active 1,25(OH)2D. Supplementation with calcitriol (prescription) rather than standard vitamin D may be necessary under medical supervision [1].

Bariatric surgery: Reduced absorption of fat-soluble vitamins including vitamin D. Screening, monitoring, and replacement are recommended before and after surgery [1].

Black Americans: Due to a genetic variant, many Black Americans have lower levels of vitamin D binding protein, allowing more bioavailable vitamin D despite lower total 25(OH)D levels. A Baltimore study found that while total levels were 15.6 ng/mL in Black vs. 25.8 ng/mL in White participants, bioavailable vitamin D was the same, and bone mineral density was actually higher in the Black group (Powe, NEJM 2013) [4]. Standard total 25(OH)D measurements may overestimate deficiency in this population.

Drug Interactions

Vitamin D Affects Drug Metabolism

Drug	Interaction	Recommendation
Thiazide diuretics	Vitamin D increases calcium absorption; combined with thiazide-reduced calcium excretion, risk of hypercalcemia increases	Monitor calcium levels, especially in older adults and those with kidney impairment [1]

Drugs That Affect Vitamin D Levels

Drug Class	Effect on Vitamin D	Notes
Orlistat (weight loss)	Reduces vitamin D absorption from food and supplements	Supplement vitamin D and separate from orlistat doses [1]
Statins	Complex bidirectional effects. Rosuvastatin may increase levels by ~23 ng/mL; atorvastatin may modestly decrease levels. All statins may reduce endogenous vitamin D synthesis	Statin users may need ~21% more vitamin D to achieve the same serum increase. Separate high-dose vitamin D from atorvastatin, lovastatin, and simvastatin as they compete for the same metabolizing enzyme (CYP3A4) [1][4]
Corticosteroids (prednisone)	Reduce calcium absorption and impair vitamin D metabolism. Deficiency was more than twice as common in oral steroid users (11%) vs. nonusers (5%)	Consider higher vitamin D doses and monitoring [1][4]
Proton pump inhibitors (PPIs)	Long-term use associated with lower vitamin D levels. In one study, 100% of pantoprazole users were deficient vs. 25% of non-users (Losurdo, J Clin Med 2023)	Monitor vitamin D in chronic PPI users [4]
Anticonvulsants	Phenobarbital, phenytoin increase vitamin D catabolism	May require higher supplement doses [1]
Cholestyramine	Reduces vitamin D absorption	Separate doses by several hours [1]
High-dose estrogen oral contraceptives	May increase vitamin D binding protein, though total levels appear unaffected	Low-dose contraceptives do not appear to have this effect (Stanczyk, J Steroid Biochem Mol Biol 2021) [4]

Dietary Sources

Few foods naturally contain vitamin D. Fortified foods provide most dietary vitamin D in the American diet [1].

Top Food Sources

Food	Serving	Vitamin D (IU)	% DV (800 IU)
Cod liver oil	1 tablespoon	1,360	170%
Trout (rainbow), farmed, cooked	3 oz	645	81%
Salmon (sockeye), cooked	3 oz	570	71%
Canned sockeye salmon	3 oz	716	90%
Canned pink salmon	3 oz	492	62%
Mushrooms (UV-exposed), raw	1/2 cup	366	46%
Milk, vitamin D fortified	1 cup	120	15%
Soy/almond/oat milk, fortified	1 cup	100-144	13-18%
Sardines (Atlantic), canned	2 sardines	46	6%
Egg, 1 large scrambled	1 egg	44	6%
Beef liver, braised	3 oz	42	5%
Light tuna, canned	3 oz	40	5%
Cheddar cheese	1.5 oz	17	2%

Source: USDA FoodData Central, NIH ODS [1][11].

Practical Notes on Food Sources

• Canned fish tends to provide more vitamin D than traditionally cooked fish [4]
• Cooking method matters: Boiling mushrooms can reduce vitamin D by 9-63%, while baking reduces it 35-47% [4]
• Fat-containing meals improve absorption: Vitamin D in foods like fish is absorbed better when consumed with dietary fat. A study found salmon consumed as a cooked sausage (16.7g fat) was more effective at maintaining vitamin D levels than the same salmon cooked normally (3.25g fat) (Utri-Khodadady, Nutrients 2024) [4]
• Animal foods contain calcifediol: The 25(OH)D form in animal tissues is approximately 5 times more potent than parent vitamin D, meaning the total vitamin D activity of beef, pork, chicken, and eggs may be 2-18 times higher than the standard vitamin D content listed [1]
• Fortification: Almost all US milk is voluntarily fortified with ~120 IU/cup. The FDA increased maximum vitamin D in breakfast cereals to 560 IU/100g in January 2023 [1][4]

Sun Exposure

Approximately 5-30 minutes of sun exposure between 10 AM and 4 PM, at least twice weekly, to the face, arms, hands, and legs without sunscreen usually leads to sufficient vitamin D synthesis in most people [1][4]. However, many factors reduce production: higher latitude, winter season, dark skin, older age, cloud cover, smog, and sunscreen use. UVB does not penetrate glass [1].

Sun exposure cannot cause vitamin D toxicity because excessive UV exposure degrades previtamin D3 [4]. Importantly, observational studies show that typical sunscreen use does not significantly reduce vitamin D levels or increase osteoporosis risk (Afarideh, JAMA Dermatol 2021; Patel, Photodermatol Photoimmunol Photomed 2022) [4], likely because people rarely apply sunscreen perfectly to all exposed skin.

In people with moderately dark skin, 30 minutes of daylight 3 times per week to hands, arms, and legs raised levels by only 0.9 ng/mL over 4 weeks, suggesting standard sun exposure recommendations may be inadequate for this population (Lee, J Korean Med Sci 2020) [4].

Magnesium and Vitamin D

Adequate magnesium intake helps maintain optimal vitamin D levels. When 25(OH)D is around 30 ng/mL, magnesium boosts conversion to 25(OH)D, raising levels by ~3 ng/mL. A study found supplementing with 51 mg magnesium plus 1,000 IU D3 daily increased 25(OH)D by 6 ng/mL, compared to only 2 ng/mL with D3 alone (Cheung, Nutrition 2022) [4]. Among 180 US adults, magnesium kept boosting D2 levels regardless of starting level, while for D3, magnesium only boosted levels up to ~30 ng/mL and then actually lowered them above that threshold — helping maintain optimal range (Dai, Am J Clin Nutr 2018) [4]. Most people do not get adequate dietary magnesium, and supplementing with approximately 200 mg can help optimize vitamin D status [4].

Exercise and Vitamin D Levels

Exercise can temporarily raise vitamin D levels. Moderate-intensity exercise (jogging for 60 minutes) increased 25(OH)D by ~2.4 ng/mL and the biologically active 1,25(OH)2D3 by ~7.28 pg/mL, possibly by releasing vitamin D from fat tissue or contracting muscles (Davies, J Physiol 2024) [4]. Levels returned to baseline within 1-24 hours. Avoid exercising for at least 1 hour before blood testing for vitamin D [4]. A 10-week winter study found exercise may prevent declines in the active form of vitamin D during winter months (Perkin, Adv Sci 2025) [4].

References

[1] National Institutes of Health, Office of Dietary Supplements. "Vitamin D — Health Professional Fact Sheet." Updated July 2024. https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/

[2] Institute of Medicine, Food and Nutrition Board. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academy Press, 2010.

[3] Norman AW, Henry HH. "Vitamin D." In: Erdman JW, Macdonald IA, Zeisel SH, eds. Present Knowledge in Nutrition, 10th ed. Washington DC: Wiley-Blackwell, 2012.

[4] ConsumerLab. "Vitamin D Supplements Review." Accessed 2026. https://www.consumerlab.com/reviews/vitamin-d-supplements-review/vitamin-d/

[5] Sempos CT, Heijboer AC, Bikle DD, et al. "Vitamin D assays and the definition of hypovitaminosis D." Br J Clin Pharmacol. 2018;84:2194-207. https://pubmed.ncbi.nlm.nih.gov/29851137/

[6] Demay MB, Pittas AG, Bikle DD, et al. "Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline." J Clin Endocrinol Metab. 2024;109(8):1907-1947. https://pubmed.ncbi.nlm.nih.gov/38828931/

[7] Shah VP, Nayfeh T, Alsawaf Y, et al. "A Systematic Review Supporting the Endocrine Society Clinical Practice Guidelines on Vitamin D." J Clin Endocrinol Metab. 2024;109(8):1961-1974. https://pubmed.ncbi.nlm.nih.gov/38828886/

[8] Munns CF, Shaw N, Kiely M, et al. "Global consensus recommendations on prevention and management of nutritional rickets." J Clin Endocrinol Metab. 2016;101:394-415. https://pubmed.ncbi.nlm.nih.gov/26745253/

[9] Tripkovic L, Lambert H, Hart K, et al. "Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: A systematic review and meta-analysis." Am J Clin Nutr. 2012;95:1357-64. https://pubmed.ncbi.nlm.nih.gov/22552031/

[10] Graeff-Armas LA, Bendik I, Kunz I, et al. "Supplemental 25-hydroxycholecalciferol is more effective than cholecalciferol in raising serum 25-hydroxyvitamin D concentrations in older adults." J Nutr. 2020;150:73-81. https://pubmed.ncbi.nlm.nih.gov/31504686/

[11] U.S. Department of Agriculture, Agricultural Research Service. FoodData Central. https://fdc.nal.usda.gov/

[12] LeBoff MS, Chou SH, Ratliff KA, et al. "Supplemental vitamin D and incident fractures in midlife and older adults." N Engl J Med. 2022;387:299-309. https://pubmed.ncbi.nlm.nih.gov/35939577/

[13] Bischoff-Ferrari HA, Willett WC, Orav EJ, et al. "A pooled analysis of vitamin D dose requirements for fracture prevention." N Engl J Med. 2012;367:40-49. https://pubmed.ncbi.nlm.nih.gov/22762317/

[14] Bolland MJ, Grey A, Avenell A. "Effects of vitamin D supplementation on musculoskeletal health." Lancet Diabetes Endocrinol. 2018;6:847-58. https://pubmed.ncbi.nlm.nih.gov/30293909/

[15] Manson JE, et al. "Vitamin D, calcium supplementation, and hip fracture in postmenopausal women." JAMA. 2024.

[16] Yao P, Bennett D, Mafham M, et al. "Vitamin D and calcium for the prevention of fracture." JAMA Network Open. 2019;2(12):e1917789. https://doi.org/10.1001/jamanetworkopen.2019.17789

[17] Manson JE, Cook NR, Lee IM, et al. "Vitamin D supplements and prevention of cancer and cardiovascular disease." N Engl J Med. 2019;380:33-44. https://pubmed.ncbi.nlm.nih.gov/30415629/

[18] Chandler PD, Chen WY, Ajala ON, et al. "Effect of vitamin D3 supplements on development of advanced cancer." JAMA Netw Open. 2020;3(11):e2025850. https://doi.org/10.1001/jamanetworkopen.2020.25850

[19] Bischoff-Ferrari HA, Vellas B, Rizzoli R, et al. "Effect of vitamin D, omega-3 fatty acids, and strength training on clinical outcomes in older adults: DO-HEALTH trial." Front Nutr. 2022.

[20] Chowdhury R, Kunutsor S, Vitezova A, et al. "Vitamin D and risk of cause specific death." BMJ. 2014;348:g1903. https://doi.org/10.1136/bmj.g1903

[21] Beveridge LA, Struthers AD, Khan F, et al. "Effect of vitamin D supplementation on blood pressure." JAMA Intern Med. 2015;175(5):745-54. https://pubmed.ncbi.nlm.nih.gov/25775274/

[22] Pittas AG, Dawson-Hughes B, Sheehan P, et al. "Vitamin D supplementation and prevention of type 2 diabetes." N Engl J Med. 2019;381:520-530. https://pubmed.ncbi.nlm.nih.gov/31173679/

[23] Martineau AR, Jolliffe DA, Hooper RL, et al. "Vitamin D supplementation to prevent acute respiratory tract infections." BMJ. 2017;356:i6583. https://doi.org/10.1136/bmj.i6583

[24] Martineau AR, Jolliffe DA, Greenberg L, et al. "Vitamin D supplementation to prevent asthma exacerbations." Cochrane Database Syst Rev. 2016;9:CD011511.

[25] Hahn J, Cook NR, Alexander EK, et al. "Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial." BMJ. 2022;376:e066452. https://doi.org/10.1136/bmj-2021-066452

[26] Jeong SH, Kim JS, Shin JW, et al. "Decreased serum vitamin D in idiopathic benign paroxysmal positional vertigo." Neurology. 2020;95(9):e1110-e1121. https://doi.org/10.1212/WNL.0000000000010122

[27] Smith LM, Gallagher JC, Suiter C. "Medium doses of daily vitamin D decrease falls and higher doses increase falls." J Steroid Biochem Mol Biol. 2017;173:317-322. https://pubmed.ncbi.nlm.nih.gov/28323044/

[28] Appel LJ, Michos ED, Mitchell CM, et al. "The effects of four doses of vitamin D supplements on falls in older adults." Ann Intern Med. 2020;174(2):145-156. https://pubmed.ncbi.nlm.nih.gov/33284677/

[29] Burt LA, Billington EO, Rose MS, et al. "Effect of high-dose vitamin D supplementation on volumetric bone density and bone strength." JAMA. 2019;322(8):736-745. https://pubmed.ncbi.nlm.nih.gov/31454046/

[30] Durup D, Jorgensen HL, Christensen J, et al. "A reverse J-shaped association between serum 25-hydroxyvitamin D and cardiovascular disease mortality." J Clin Endocrinol Metab. 2012;97(8):2644-2652. https://pubmed.ncbi.nlm.nih.gov/22573406/

[31] Fan X, Wang J, Song M, et al. "Vitamin D status and risk of all-cause and cause-specific mortality in a large cohort." J Clin Endocrinol Metab. 2020;105(10):e3606-e3620.

[32] Sutherland JP, Zhou A, Leach MJ, Hypponen E. "Differences and determinants of vitamin D deficiency among UK biobank participants." Ann Intern Med. 2022.

[33] Littlejohns TJ, Henley WE, Lang IA, et al. "Vitamin D and the risk of dementia and Alzheimer disease." Neurology. 2014;83(10):920-928. https://pubmed.ncbi.nlm.nih.gov/25098535/

[34] McCullough ML, Zoltick ES, Weinstein SJ, et al. "Circulating vitamin D and colorectal cancer risk." J Natl Cancer Inst. 2018.

[35] Kristal AR, Till C, Song X, et al. "Plasma vitamin D and prostate cancer risk." Cancer Epidemiol Biomarkers Prev. 2014;23(8):1494-504. https://pubmed.ncbi.nlm.nih.gov/24732039/

[36] Neale RE, Baxter C, Romero BD, et al. "The D-Health Trial: a randomized trial of the effect of vitamin D on mortality." Lancet Diabetes Endocrinol. 2022;10(2):120-128.

[37] Zittermann A, Ernst JB, Prokop S, et al. "Effect of vitamin D on all-cause mortality in heart failure (EVITA)." Eur Heart J. 2017;38:2279-86.

[38] National Heart, Lung, and Blood Institute PETAL Clinical Trials Network. "Early high-dose vitamin D3 for critically ill, vitamin D-deficient patients." N Engl J Med. 2019;381:2529-40.

[39] Dai Q, Zhu X, Manson JE, et al. "Magnesium status and supplementation influence vitamin D status and metabolism." Am J Clin Nutr. 2018;108(6):1249-1258. https://pubmed.ncbi.nlm.nih.gov/30541089/